Dr. John Phillips, MD
Medical Genetics (Clinical Genetics (M.D.) Physician)
At a glance
- Medical school
- Wake Forest University School of Medicine (1969)
- Years since graduation
- 57
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1969Medical school: Wake Forest University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Clinical Genetics (M.D.) Physician primary
TN license MD15808 -
Pediatrics Physician
TN license MD15808
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Vanderbilt University Medical Center Nashville, TN
Medical groups
- Vanderbilt University Medical Center (3,567 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 1 companies. The companies reported $148,641 in research payments for these studies, mostly to the institutions running them.
- A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia
BioMarin Pharmaceutical Inc. - BMN 165-501
BioMarin Pharmaceutical Inc. - BMN 165-503
BioMarin Pharmaceutical Inc. - A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children With Achondroplasia
BioMarin Pharmaceutical Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.